Buy Rating Affirmed for scPharmaceuticals Amid Furoscix Success and Market Expansion

scPharmaceuticals (SCPH – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Stacy Ku from TD Cowen maintained a Buy rating on the stock and has a $25.00 price target.

Stacy Ku has given his Buy rating due to a combination of factors including the successful launch and adoption of Furoscix, scPharmaceuticals’s subcutaneous treatment for heart failure patients suffering from fluid overload. The strong quarterly revenue growth, alignment with consensus despite external challenges, and a high demand for the product underscore its market acceptance. Ku’s confidence is further bolstered by the positive feedback from healthcare professionals and patients on Furoscix’s efficacy and ease of use, which is pivotal as it serves a significant patient population with an unmet medical need.

Moreover, Ku is optimistic about the company’s strategic educational initiatives aimed at broadening the reach to more heart failure practices, which is evident from the impressive growth in healthcare professionals prescribing Furoscix. The anticipation of a manageable copay for patients and a high demand for doses suggest a strong market penetration potential. The company’s plans to expand the salesforce and its ability to meet the projected sales targets for 2024 reinforce Ku’s belief in the product’s future success and justify the Buy rating for scPharmaceuticals.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

scPharmaceuticals (SCPH) Company Description:

scPharmaceuticals, Inc.engages in the development of transformative pharmaceutical products for subcutaneous delivery. Its products include furosemide, used as parenteral diuretic in treating heart failure and ceftriaxone, used as parenteral antibiotic outside the hospital setting. The company was founded by Pieter Muntendam and Bertram Pitt in February 2013 and is headquartered in Burlington, MA.